
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc is positioned favorably in the biopharmaceutical sector, primarily driven by the ongoing success of its flagship drug cabozantinib (Cabo), which is gaining traction in renal cell carcinoma (RCC) and showing promise in neuroendocrine tumors (NETs) following recent label expansions. Additionally, the combination therapy of zanzalintinib with atezolizumab has demonstrated statistically significant improvements in median overall survival, further solidifying the company's portfolio in targeted cancer therapies. The company's ability to generate continued positive data outcomes and expand treatment indications supports a robust outlook for future growth and market performance.
Bears say
Exelixis, Inc. faces significant financial headwinds due to an anticipated 80% decline in revenues following the patent expiration of its key product, cabozantinib, by 2031, a forecast more severe than the market consensus of 68% reduction. Additionally, the company is exposed to competitive risks, including market share erosion for cabozantinib in renal cell carcinoma (RCC) and potential failures in approval timelines for other treatments in its pipeline, particularly zanzalintinib. Ultimately, these factors have led to concerns regarding the sustainability of revenue growth and overall share valuation, warranting a cautious outlook on the company's future financial performance.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares